

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equality issues identified
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Not applicable
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
Not applicable

Approved by Associate Director (name): ...Janet Robertson.....

Date: 13 May 2024